Janux Pharma - JANX Net earnings per share for the last four quarters

Official company branding of Janux Pharma (JANX)

Janux Therapeutics (JANX) potential is growing driven by the TRACTR platform and toxicity protection. Demand for such treatments is independent of economic conditions, ensuring stability. The year-over-year EPS trend (trailing 12 months) clearly demonstrates these trends, where the 4.90 level captures the current state. High R&D expenditures and patent monopolies create insurmountable barriers for competitors.

Janux Therapeutics, Inc. (JANX) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

JANX (Janux Therapeutics, Inc.): analytical breakdowns and indicator data

Initial company analysis:JANX, Janux Pharma
Mass-produced product of januxrx.com

This indicator measures the rate of change in net earnings per share over the last twelve months, allowing for an assessment of real capital efficiency without quarterly fluctuations. The current annual EPS growth (ttm) value of 4.90 reflects the financial performance of Janux Therapeutics (JANX) amid the rapid advancement of their innovative high-precision immunotherapy programs for oncological diseases.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months